HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Blades and Razors sales advanced 11% to $1.21 bil. on a reported basis, and profit from operations in the unit increased 16% to $488 mil. in the second quarter, Gillette announces Aug. 4. Results were boosted in part by a double-digit sales increase in North America for the Venus women's shaving brand, which benefited from the launch of Venus Vibrance and new Venus Disposable razor. Gillette's global value share of the blades/razors segment increased by more than one percentage point to 71.5%, while M3Power remained the top-selling men's razor in North America and worldwide with a 19% value share, according to the firm. Personal care sales were up 9% to $256 mil., with profit from operations advancing 25% to $30 mil., reflecting improved product mix and "ongoing trade-up from shaving foams to gels," company notes. Net sales rose 13.4% to $2.77 bil., while net income increased 16.9% to $498 mil...

You may also be interested in...

E.l.f. Puts Premium On ‘Clean Beauty’ With First Strategic Acquisition: W3ll People

W3ll People is expected to add a relatively modest $7m to e.l.f. Beauty’s fiscal 2021 top line, but the brand has “major white space” opportunities, including at Target, e.l.f.’s longest-standing customer. Further, its plant-based product line includes 40 “EWG Verified” products, reflecting expertise e.l.f. is eager to tap.

UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline

UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.


New Indications For Diabetes Drugs Under The Spotlight At EMA

Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts